Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 5/20 | 0.80 |
| ▸ | RET | P07949 | 3/20 | 0.80 |
| ▸ | SRC | P12931 | 3/20 | 0.80 |
| ▸ | DYRK3 | O43781 | 2/20 | 0.80 |
| ▸ | CDK1 | P06493 | 2/20 | 0.80 |
| ▸ | ROS1 | P08922 | 2/20 | 0.80 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.80 |
| ▸ | CDK2 | P24941 | 2/20 | 0.80 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.80 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.80 |
| ▸ | CLK2 | P49760 | 2/20 | 0.80 |
| ▸ | IRAK1 | P51617 | 2/20 | 0.80 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.80 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.80 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.80 |
| ▸ | SLK | Q9H2G2 | 2/20 | 0.80 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.80 |
| ▸ | JAK2 | O60674 | 2/20 | 0.80 |
| ▸ | CDC7 | O00311 | 1/20 | 0.80 |
| ▸ | PLK4 | O00444 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22243320 | 0.90 | KDR (0.87) | KDRRETSRCDYRK3CDK1 | |
| SCHEMBL6109043 | 0.89 | KDR (1.00) | KDRRETSRCDYRK3CDK1 | |
| SCHEMBL6109435 | 0.89 | KDR (1.00) | KDRRETSRCDYRK3CDK1 | |
| SCHEMBL6109045 | 0.89 | KDR (1.00) | KDRRETSRCDYRK3CDK1 | |
| SCHEMBL20533184 | 0.88 | SRC (0.67) | KDRRETSRCDYRK3CDK1 | |
| SCHEMBL22243341 | 0.88 | KDR (0.74) | KDRRETSRCDYRK3CDK1 | |
| SCHEMBL22243293 | 0.88 | KDR (0.74) | KDRRETSRCDYRK3CDK1 | |
| SCHEMBL24096480 | 0.86 | JAK2 (0.86) | KDRRETSRCDYRK3CDK1 | |
| SCHEMBL20533742 | 0.84 | RET (0.68) | KDRRETSRCDYRK3CDK1 | |
| SCHEMBL1318717 | 0.84 | SRC (0.77) | KDRRETSRCDYRK3CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3009436-B1 | KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC (US) | 2019-06-05 | — | — | EP | disclosed |
| US-9828378-B2 | Kinase inhibitors and methods of use | INTELLIKINE LLC (US) | 2017-11-28 | — | — | US | disclosed |
| US-9828378-B2 | Kinase inhibitors and methods of use | INTELLIKINE LLC (US) | 2017-11-28 | — | — | US | disclosed |
| EP-3009436-A1 | KINASE INHIBITORS AND METHODS OF USE | Intellikine, LLC (US) | 2016-04-20 | — | — | EP | disclosed |
| US-20160024099-A1 | KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC | 2016-01-28 | — | — | US | disclosed |
| US-20160024099-A1 | KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC | 2016-01-28 | — | — | US | disclosed |
| EP-2313414-B1 | KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC (US) | 2015-11-04 | — | — | EP | disclosed |
| US-9096611-B2 | Kinase inhibitors and methods of use | INTELLIKINE LLC (US) | 2015-08-04 | — | — | US | disclosed |
| US-9096611-B2 | Kinase inhibitors and methods of use | INTELLIKINE LLC (US) | 2015-08-04 | — | — | US | disclosed |
| US-20110172228-A1 | KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC | 2011-07-14 | — | — | US | disclosed |
| US-20110172228-A1 | KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC | 2011-07-14 | — | — | US | disclosed |
| WO-2010006086-A2 | KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE, INC. (US) | 2010-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172228-A1 | KINASE INHIBITORS AND METHODS OF USE | PIK3CA, MTOR, PDPK1 | KDR 698/4885RET 443/4885SRC 54/4885 |
| US-20160024099-A1 | KINASE INHIBITORS AND METHODS OF USE | PIK3CA, MTOR, PDPK1 | KDR 698/4885RET 443/4885SRC 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.